StreetInsider.com News Articles

Form 8-K ACCENDRA HEALTH INC/VA/ For: Aug 17

Mon, 17 Aug 2026 06:42:00 -0400

si-local-file:///var/storage/secattach/20260817/26934544.html

Form 8-K ACCENDRA HEALTH INC/VA/ For: Aug 17

Mon, 17 Aug 2026 06:42:00 -0400

si-local-file:///var/storage/secattach/20260817/26934544.html

Accendra Health scraps equity program, expects CEO successor by mid-2026

Mon, 17 Aug 2026 06:30:34 -0400

Accendra Health (NYSE: ACH) said it will not proceed with a planned at-the-market equity issuance program, citing recent market conditions, and provided an updated timeline for replacing its chief executive officer.

The company said the decision to cancel the program, which was designed to allow modest equity issuances over time with proceeds earmarked for debt reduction, will have no impact on its results of operations or published guidance.

Accendra said it remains confident in its liquidity position, noting improving cash collections and progress in resolving payor collection issues. The company was undrawn on its $300 million revolving credit facility at the end

Accendra Health scraps equity program, expects CEO successor by mid-2026

Mon, 17 Aug 2026 06:30:34 -0400

Accendra Health scraps equity program, expects CEO successor by mid-2026

Mon, 17 Aug 2026 06:30:34 -0400

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

Mon, 17 Aug 2026 06:30:00 -0400

RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer.

Given recent market conditions, the Company has determined that it is in the best interest of stakeholders not to put in place an at-the-market issuance program. The program was intended to allow the Company to opportunistically issue modest amounts of equity over time, with the proceeds to be used to reduce outstanding indebtedness, including debt trading at discounts to par value. The program was never intended as a source of liquidity

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

Mon, 17 Aug 2026 06:30:00 -0400

RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer.

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

Mon, 17 Aug 2026 06:30:00 -0400

RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer.

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

Mon, 17 Aug 2026 06:30:00 -0400

RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer.

Accendra Health Inc. (ACH) PT Lowered to $1.50 at UBS

Thu, 13 Aug 2026 09:15:34 -0400

UBS analyst Kevin Caliendo lowered the price target on Accendra Health Inc. (NYSE: ACH) to $1.50 (from $4.50) while maintaining a Neutral rating.

Baird Downgrades Accendra Health Inc. (ACH) to Neutral

Tue, 11 Aug 2026 02:49:37 -0400

Baird analyst Eric Coldwell downgraded Accendra Health Inc. (NYSE: ACH) from Outperform to Neutral with a price target of $1.50 (from $6.00).

The analyst comments: “Downgrade to Neutral with $1.50 price target; moving Suitability to Speculative Risk. Results underwhelmed, much of which was driven by long-standing internal issues. Guidance can’t be relied on, particularly during a CEO exit. Competitive bidding looms. From here, stock may rally big on any good news, but it’s small dollars and not worth the risk, in our view. Our biggest holdup: ACH likely won’t be institutionally relevant for years ahead as a micro-cap with an active

Baird Downgrades Accendra Health Inc. (ACH) to Neutral

Tue, 11 Aug 2026 02:49:37 -0400

Baird analyst Eric Coldwell downgraded Accendra Health Inc. (NYSE: ACH) from Outperform to Neutral with a price target of $1.50 (from $6.00).

Accendra Health Inc. (ACH) PT Lowered to $1.30 at BofA Securities

Mon, 10 Aug 2026 16:40:56 -0400

BofA Securities analyst Allen Lutz lowered the price target on Accendra Health Inc. (NYSE: ACH) to $1.30 (from $2.70) while maintaining a Underperform rating.

Citi Downgrades Accendra Health Inc. (ACH) to Neutral

Mon, 10 Aug 2026 16:32:17 -0400

Citi analyst Daniel Grosslight downgraded Accendra Health Inc. (NYSE: ACH) from Buy to Neutral with a price target of $1.50 (from $4.50).

For an analyst ratings summary and ratings history on Accendra Health Inc. click here. For more ratings news on Accendra Health Inc. click here.

Shares of Accendra Health Inc. closed at $2.80 yesterday.

Citi Downgrades Accendra Health Inc. (ACH) to Neutral

Mon, 10 Aug 2026 16:32:17 -0400

Citi analyst Daniel Grosslight downgraded Accendra Health Inc. (NYSE: ACH) from Buy to Neutral with a price target of $1.50 (from $4.50).

For an analyst ratings summary and ratings history on Accendra Health Inc. click here. For more ratings news on Accendra Health Inc. click here.

Shares of Accendra Health Inc. closed at $2.80 yesterday.

Form 8-A12B ACCENDRA HEALTH INC/VA/

Mon, 10 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260810/26898271.html

Form 8-A12B ACCENDRA HEALTH INC/VA/

Mon, 10 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260810/26898271.html

Form 8-K ACCENDRA HEALTH INC/VA/ For: Aug 09

Mon, 10 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260810/26898140.html

Form 8-K ACCENDRA HEALTH INC/VA/ For: Aug 09

Mon, 10 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260810/26898140.html

Accendra Health Inc. (ACH) PT Lowered to $1.75 at Leerink

Mon, 10 Aug 2026 13:43:37 -0400

Leerink analyst Michael Cherny lowered the price target on Accendra Health Inc. (NYSE: ACH) to $1.75 (from $4.25) while maintaining a Market Perform rating.

Form 10-Q ACCENDRA HEALTH INC/VA/ For: Jun 30

Mon, 10 Aug 2026 11:16:00 -0400

si-local-file:///var/storage/secattach/20260810/26896115.html

Form 10-Q ACCENDRA HEALTH INC/VA/ For: Jun 30

Mon, 10 Aug 2026 11:16:00 -0400

si-local-file:///var/storage/secattach/20260810/26896115.html

Accendra Health, Inc. (ACH) Misses Q2 EPS by 31c ; Offers Guidance

Mon, 10 Aug 2026 08:18:03 -0400

Accendra Health, Inc. (NYSE: ACH) reported Q2 EPS of ($0.19), $0.31 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $613.2 million versus the consensus estimate of $632.21 million.

FY 2026 Outlook:-
Revenue between $2.45 billion - $2.55 billion vs consensus $2.57 billion.

For earnings history and earnings-related data on Accendra Health, Inc. (ACH) click here.

Accendra Health adopts plan to guard tax assets from ownership shifts

Mon, 10 Aug 2026 06:51:04 -0400

Accendra Health, Inc. (NYSE: ACH) said its board of directors adopted a Section 382 Rights Agreement, known as a Tax Asset Preservation Plan, aimed at protecting the company's net operating loss carryforwards and certain other tax attributes.

The plan took effect on August 10, 2026, and is scheduled to remain in place until August 10, 2029, unless terminated earlier under its terms.

The plan is designed to reduce the likelihood of an "ownership change" under Section 382 of the Internal Revenue Code by deterring any person or group from acquiring beneficial ownership of 4.9% or more of the company's outstanding common stock.

Form 8-K ACCENDRA HEALTH INC/VA/ For: Aug 10

Mon, 10 Aug 2026 06:50:00 -0400

si-local-file:///var/storage/secattach/20260810/26893949.html